Dulaglutide
Also known as: Trulicity
Dulaglutide is a catalog-expanded glp1 entry in ProtoComp's source-backed compound corpus. It is included for search, calculator math, stack awareness, and future research curation based on expand compound catalog, explicit_target_list, local_seed, peptidejournal, peptidejournal_fda_peptide_list, project_target, wiki_glp1, wikipedia_table. Published dosing, cycle length, and clinical-use claims are intentionally left null until compound-specific evidence is reviewed.
FDA-approved weekly GLP-1 RA for T2D. Titrate 0.75 then 1.5 then 3 then 4.5 mg weekly, at least 4 weeks between steps.
No published cycle data available.
Consistent day of week.
Contraindications
- • Personal or family history of medullary thyroid carcinoma (MTC)
- • Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
- • History of pancreatitis
Common side effects
- • Nausea
- • Diarrhea
- • Vomiting
- • Abdominal pain
- • Decreased appetite
Serious risks
- • Acute pancreatitis
- • Gallbladder disease
- • Kidney injury from dehydration
- • Thyroid C-cell tumors (boxed warning)
Drug interactions
- • Insulin/sulfonylureas (hypoglycemia risk)
Requires monitoring
- • HbA1c
- • Kidney function
Pregnancy / breastfeeding
Not recommended during pregnancy
- Weight loss effect is smaller than Semaglutide or Tirzepatide at approved doses
Sign in to calculate your dose, add this compound to your stack, and check for interactions with your current cabinet.